Patent · US Active

Surface-oriented antibody coating for the reduction of post-stent restenosis

US9150646B2 · kind B2 · utility

0Cited by
3References
7Claims
0Family size

Assignee

Inventors

Key dates

Filing dateSep 12, 2011
Grant dateOct 6, 2015
Priority date
Expiry dateJul 11, 2034

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/55
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

A coating for a surface of a surgical implant, the coating including a binding protein for capturing cells to the surface via a bi-functional linker molecule. The linker can have a first functional group (such as a trichlorosilyl group) for covalently linking to the surface, and a second functional group (such as a benzothiosulfonate group) for covalently linking to the binding protein. One exemplary linker molecule is S-(11-trichlorosilyl-undecenyl)benzenethiosulfonate. The coating may be a self-assembled monolayer and may also include a spacer molecule, which can be unreactive with the binding protein. The target cells may be endothelial stem cells (such as endothelial progenitor cells). The binding protein may be an antibody, antibody fragment or non-antibody derived antigen binding molecule. The binding protein may bind a cell surface marker specific to target cell type. Coated surgical implants, and methods of forming such a coating are also contemplated.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.